AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 102 filers reported holding AMYLYX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $842 | -99.5% | 46 | -99.4% | 0.00% | – |
Q2 2023 | $153,298 | -98.4% | 7,107 | -97.8% | 0.00% | -100.0% |
Q1 2023 | $9,529,632 | -87.9% | 324,800 | -84.7% | 0.03% | -88.8% |
Q4 2022 | $78,628,122 | +498.2% | 2,127,960 | +355.7% | 0.27% | +403.8% |
Q3 2022 | $13,145,000 | +118.4% | 466,961 | +49.4% | 0.05% | +112.0% |
Q2 2022 | $6,018,000 | – | 312,461 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Perceptive Advisors | 5,472,033 | $154,038,000 | 4.47% |
Ghost Tree Capital, LLC | 550,000 | $15,483,000 | 4.35% |
Ghost Tree Capital, LLC | 500,000 | $14,075,000 | 3.95% |
Bain Capital Life Sciences Investors, LLC | 1,023,214 | $28,803,000 | 3.44% |
Boxer Capital, LLC | 2,084,000 | $58,665,000 | 3.30% |
Alpha Wave Global, LP | 700,635 | $19,723,000 | 2.33% |
Soleus Capital Management, L.P. | 429,336 | $12,086,000 | 1.64% |
Ikarian Capital, LLC | 250,000 | $7,037,000 | 1.40% |
Cormorant Asset Management, LP | 610,000 | $17,172,000 | 1.20% |
SECTORAL ASSET MANAGEMENT INC | 205,400 | $5,782,000 | 1.14% |